invIOs raises EUR8.2 million in a Series A to finance pipeline progress in immuno-oncology
Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of mechanism of action expected in Q1 2025 Cell therapy INV441: pre-IND meeting with US FDA successfully completed; first-in-humans study in glioblastoma to start mid-2025 as […]